Letters to the Editor

• Comprehensive geriatric assessment is still needed in TAVI candidates at low surgical risk

  Magali González-Colaço Harmand, Miguel Leiva Gordillo, Myriel López Tatis, Francisco Ignacio Bosa Ojeda

  Rev Esp Cardiol. 2020;73:341

• Scientific evidence versus expert opinion. Should we modify clinical practice guidelines?

  Pilar Jiménez Quevedo, Manuel Pan, Raúl Moreno, Armando Pérez de Prado

  Rev Esp Cardiol. 2020;73:187-9

• Ventricular mural architecture. Response

  Omar Yassef Antúnez Montes, Alberto Sosa Olavarría, Mladen J. Kocica

  Rev Esp Cardiol. 2020;73:187

• Ventricular mural architecture

  Damián Sánchez-Quintana, Peter Agger, Robert H. Anderson

  Rev Esp Cardiol. 2020;73:186

• Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE

  Antonio Gippini, Alberto Prado

  Rev Esp Cardiol. 2019;72:1095-6

• Galectin-3, Carbohydrate Antigen 125 and Transcatheter Aortic Valve Implantation

  Beuy Joob, Viroj Wiwanitkit

  Rev Esp Cardiol. 2019;72:983

• Are There Gaps in the Evidence on the Treatment of Mild Hypertension in Patients With Low Cardiovascular Risk? Response

  Antonio Coca, Pilar Mazón, Francisco Marín

  Rev Esp Cardiol. 2019;72:886

• Are There Gaps in the Evidence on the Treatment of Mild Hypertension in Patients With Low Cardiovascular Risk?

  Alberto Morales-Salinas

  Rev Esp Cardiol. 2019;72:885-6

• Factors Impacting Prognosis Among Patients with Tako-tsubo Syndrome

  Nauman Khalid, Sarah Aftab Ahmad, Affan Umer, Lovely Chhabra

  Rev Esp Cardiol. 2019;72:694

• Factors Impacting Prognosis Among Patients with Tako-tsubo Syndrome. Response

  Alberto Pérez-Castellanos, Manuel Martínez-Sellés, Bernardo García de la Villa, Iván J. Núñez-Gil

  Rev Esp Cardiol. 2019;72:694-5

• Definition of Myocardial Infarction Type 4a: Can We Define Its Diagnosis and Systematize Clinical Practice?

  Iñigo Lozano, Juan Rondán, José M. Vegas, Eduardo Segovia

  Rev Esp Cardiol. 2019;72:695-6

• Definition of Myocardial Infarction Type 4a: Can We Define Its Diagnosis and Systematize Clinical Practice? Response

  Antonia Sambola, Ana Viana Tejedor, Pilar Jiménez-Quevedo, Fernando Alfonso

  Rev Esp Cardiol. 2019;72:696

• Validity of the Minimum Basic Data Set for Research Into Outcomes of the Care of Acute Coronary Syndrome

  José Eduardo Calle-Urra, Pedro Parra-Hidalgo, Eduardo Pinar-Bermúdez, Concepción López-Rojo

  Rev Esp Cardiol. 2019;72:696-7

• Validity of the Minimum Basic Data Set for Research Into Outcomes of the Care of Acute Coronary Syndrome. Response

  José Luis Bernal, José A. Barrabés, Cristina Fernández-Pérez, Francisco Javier Elola

  Rev Esp Cardiol. 2019;72:697-8

• Vaccination in Patients With Heart Disease. How Long Should We Wait? Response

  Nikolaos P.E. Kadoglou, John Parissis, Petar Seferovic, Gerasimos Filippatos

  Rev Esp Cardiol. 2019;72:516

• In-hospital Mortality Due to Acute Myocardial Infarction in the Canary Islands

  Marta María Martín Cabeza, Pablo Jorge Pérez, Martín Jesús García González

  Rev Esp Cardiol. 2019;72:516-7

• In-hospital Mortality Due to Acute Myocardial Infarction in the Canary Islands. Response

  María del Cristo Rodríguez-Pérez, Itahisa Marcelino Rodríguez, Arturo J. Pedrero García, Antonio Cabrera de León

  Rev Esp Cardiol. 2019;72:517-8

• Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors

  Alberto Cordero, Lorenzo Fácila, Enrique Galve, José Ramón González Juanatey

  Rev Esp Cardiol. 2019;72:518-9

• Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response

  Alberto Zamora, Luis Masana, Nuria Plana, Rafel Ramos

  Rev Esp Cardiol. 2019;72:519-20

• Vaccination in Patients With Heart Disease. How Long Should We Wait?

  Vivencio Barrios, Carlos Escobar

  Rev Esp Cardiol. 2019;72:515